News for Adaptive Biotechnologies Corporation (ADPT)

Grindr Inc. (NYSE: GRND), the Global Gayborhood in Your Pocketâ„¢, today announced the appointment of Chad Cohen, former Chief Financial Officer of Zillow Grou

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging more than 300 points on Friday. The Dow traded up 1.43% to 41,337.37 whi...

U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Friday. Shares of Trupanion, Inc. TRUP rose sharply during Friday's session afte...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ETCompany ParticipantsKarina Calzadilla - Head of...

The following slide deck was published by Adaptive Biotechnologies Corporation in conjunction with their 2025 Q1 earnings call.

The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

On Wednesday, April 23, 2025, Cathie Wood of Ark Invest purchased more stock of AMD and Nvidia amid looming US chip curbs against China.

Shares of Calix, Inc. CALX rose sharply in today's pre-market trading as the company reported better-than-expected first-quarter financial results and issued st...

SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ( ADPT), a commercial stage biotechnology company that aims to translate the

**media[591999]**

U.S. stock futures were lower this morning, with the Dow futures falling more than 1,200 points on Friday. Shares of Guess?, Inc. GES fell sharply in today's p...

Shares of Sangamo Therapeutics, Inc. SGMO rose sharply in today's pre-market trading after the company announced a new agreement with pharmaceutical giant Eli L...

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Friday. Shares of Scholastic Corporation SCHL rose sharply during Friday's sessio...

Adaptive Biotechnologies (NASDAQ:ADPT) stock rises as Goldman Sachs upgrades to 'Buy,' citing an attractive end market. Read more here.

Enhanced assay granted approval by New York State's Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD assay availa

On Friday, Cathie Wood-led Ark Invest made significant trades involving Beam Therapeutics Inc. BEAM, Nu Holdings Ltd. NU, MercadoLibre Inc. MELI, and Adaptive B...

Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here is how Adaptive Biotechnologies (ADPT) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.

Earnings Call Insights: Adaptive Biotechnologies (NASDAQ:ADPT) Q4 2024Management ViewCEO Chad Robins highlighted a strong year for Adaptive Biotechnologies,...